Not only are drugs that could treat more than one disease being disincentivized, small molecule medicines, which play an important role in treating neurological disorders, cancers, and other diseases, may also be disadvantaged by the law.

Source: https://medcitynews.com/2023/08/the-inflation-reduction-acts-impact-on-drug-development-for-rare-diseases/

They could also be disincentivized to act simply because the "proof" is hard to find scalably.

Source: https://searchengineland.com/google-local-services-ads-arbitrage-387645